Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice

Molecular Medicine

Volumn 17, Issue 7-8, 2011, Pages 599-606

  Satapathy, Sanjaya K ^a   Ochani, Mahendar ^b   Dancho, Meghan ^b   Hudson, Laqueta K ^b   Rosas Ballina, Mauricio ^b   Valdes Ferrer, Sergio I ^b   Olofsson, Peder S ^b   Harris, Yael Tobi ^a,b   Roth, Jesse ^b   Chavan, Sangeeta ^b   Tracey, Kevin J ^b   Pavlov, Valentin A ^b  

^a North Shore Long Island Jewish Health System ^*  (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; CHOLESTEROL; CYTOKINE; GALANTAMINE; ISOPHANE INSULIN; SODIUM CHLORIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLINERGIC SYSTEM; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

ADIPOKINES; ADIPOSITY; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; CHOLINESTERASE INHIBITORS; CYTOKINES; DIET, HIGH-FAT; EATING; FASTING; FATTY LIVER; GALANTAMINE; INFLAMMATION; INSULIN; MALE; MICE; MICE, INBRED C57BL; OBESITY; RESISTIN; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 79960740892     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00083     Document Type: Article

References (60)

1. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. (2007) The epidemiology of obesity. Gastroenterology. 132:2087-102.
2. Eckel RH. (2007) Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc. Nutr. Soc. 66:82-95.
3. Cornier MA, et al. (2008) The metabolic syndrome. Endocr. Rev. 29:777-822.
4. Ford ES. (2005) Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 28:2745-9.
5. Grundy SM. (2008) Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 28:629-36.
6. Dekker JM, et al. (2005) Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 112:666-73.
7. Greenfield V, Cheung O, Sanyal AJ. (2008) Recent advances in nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol. 24:320-7.
8. Satapathy SK, Sanyal AJ. (2010) Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol. Metab. 21:668-75.
9. Shoelson SE, Herrero L, Naaz A. (2007) Obesity, inflammation, and insulin resistance. Gastroenterology. 132:2169-80.
10. Olefsky JM, Glass CK. (2010) Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72:219-46.
11. Sutherland JP, McKinley B, Eckel RH. (2004) The metabolic syndrome and inflammation. Metab. Syndr. Relat. Disord. 2:82-104.
12. Festa A, et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 102:42-7.
13. Pavlov VA, et al. (2009) Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav. Immun. 23:41-5.
14. Tracey KJ. (2002) The inflammatory reflex. Nature. 420:853-9.
15. Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. (2003) The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol. Med. 9:125-34.
16. Pavlov VA, Tracey KJ. (2005) The cholinergic anti-inflammatory pathway. Brain Behav. Immun. 19:493-9.
17. Pavlov VA, et al. (2006) Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc. Natl. Acad. Sci. U. S. A. 103:5219-23.
18. Tracey KJ. (2007) Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 117:289-96.
19. Parrish WR, et al. (2008) Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol. Med. 14:567-74.
20. Pavlov VA. (2008) Cholinergic modulation of inflammation. Int. J. Clin. Exp. Med. 1:203-12.
21. Tracey KJ. (2009) Reflex control of immunity. Nat. Rev. Immunol. 9:418-28.
22. Mlinar B, Marc J, Janez A, Pfeifer M. (2007) Molecular mechanisms of insulin resistance and associated diseases. Clin. Chim. Acta. 375:20-35.
23. Li Z, et al. (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 37:343-50.
24. Tilg H, Moschen AR. (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6:772-83.
25. Hill JO, Peters JC. (1998) Environmental contributions to the obesity epidemic. Science. 280:1371-4.
26. Surwit RS, et al. (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism. 44:645-51.
27. Winzell MS, Ahren B. (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes. 53 Suppl 3:S215-9.
28. Collins S, Martin TL, Surwit RS, Robidoux J. (2004) Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol. Behav. 81:243-8.
29. Bose M, et al. (2008) The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J. Nutr. 138:1677-83.
30. Vieira VJ, et al. (2009) Effects of exercise and lowfat diet on adipose tissue inflammation and metabolic complications in obese mice. Am. J. Physiol. Endocrinol. Metab. 296:E1164-71.
31. Capsoni S, Giannotta S, Cattaneo A. (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. U. S. A. 99:12432-7.
32. Svedberg MM, Bednar I, Nordberg A. (2004) Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase. Neuropharmacology. 47:558-71.
33. Jin K, Xie L, Mao XO, Greenberg DA. (2006) Alzheimer's disease drugs promote neurogenesis. Brain Res. 1085:183-8.
34. Park JE, Lee ST, Im WS, Chu K, Kim M. (2008) Galantamine reduces striatal degeneration in 3- nitropropionic acid model of Huntington's disease. Neurosci. Lett. 448:143-7.
35. Jo YH, Wiedl D, Role LW. (2005) Cholinergic modulation of appetite-related synapses in mouse lateral hypothalamic slice. J. Neurosci. 25:11133-44.
36. Jo YH, Talmage DA, Role LW. (2002) Nicotinic receptor- mediated effects on appetite and food intake. J. Neurobiol. 53:618-32.
37. Marrero MB, et al. (2010) An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J. Pharmacol. Exp. Ther. 332:173-80.
38. Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A. (2001) Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 15 Suppl 1:S19-25.
39. Waldburger JM, et al. (2008) Spinal p38 MAP kinase regulates peripheral cholinergic outflow. Arthritis Rheum. 58:2919-21.
40. Kreier F, et al. (2002) Selective parasympathetic innervation of subcutaneous and intra-abdominal fat-functional implications. J. Clin. Invest. 110:1243-50.
41. Fantuzzi G. (2005) Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 115:911-9.
42. Kanda H, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116:1494-505.
43. Lumeng CN. (2010) Adipose tissue macrophages: a piece of the PAI of metabolic syndrome. Sci. Transl. Med. 2:20 ps7.
44. Brunt EM. (2010) Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 7:195-203.
45. Verrijken A, et al. (2010) Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int. J. Obes. (Lond.) 34:899-907.
46. Ruhl CE, Everhart JE. (2010) Trunk fat is associated with increased serum levels of alanine aminotransferase in the United States. Gastroenterology. 138:1346-56, 1356.e1-3.
47. Goessling W, et al. (2008) Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 135:1935-44, 1944e.1.
48. Xie H, Lautt WW. (1996) Insulin resistance caused by hepatic cholinergic interruption and reversed by acetylcholine administration. Am. J. Physiol. 271:E587-92.
49. Latour MG, Lautt WW. (2002) The hepatic vagus nerve in the control of insulin sensitivity in the rat. Auton. Neurosci. 95:125-30.
50. Teff KL. (2008) Visceral nerves: vagal and sympathetic innervation. JPEN J. Parenter. Enteral. Nutr. 32:569-71.
51. Lam CK, et al. (2010) Activation of NMDA receptors in the dorsal vagal complex lowers glucose production. J. Biol. Chem. 285:21913-21.
52. Pocai A, Obici S, Schwartz GJ, Rossetti L. (2005) A brain-liver circuit regulates glucose homeostasis. Cell Metab. 1:53-61.
53. Pocai A, et al. (2005) Hypothalamic K(ATP) channels control hepatic glucose production. Nature. 434:1026-31.
54. German J, et al. (2009) Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology. 150:4502-11.
55. Shimazu T, Matsushita H, Ishikawa K. (1976) Cholinergic stimulation of the rat hypothalamus: effects of liver glycogen synthesis. Science. 194:535-6.
56. Richter WO, Geiss HC, Aleksic S, Schwandt P. (1996) Cardiac autonomic nerve function and insulin sensitivity in obese subjects. Int. J. Obes. Relat. Metab. Disord. 20:966-9.
57. Karason K, Molgaard H, Wikstrand J, Sjostrom L. (1999) Heart rate variability in obesity and the effect of weight loss. Am. J. Cardiol. 83:1242-7.
58. Yaffe K, et al. (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 292:2237-42.
59. Perry VH, Cunningham C, Holmes C. (2007) Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 7:161-7.
60. Holmes C, et al. (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology. 73:768-74.